Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab, Pertuzumab, and Sandostatin in Advanced Neuroendocrine Cancers
NCT01121939Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- May 2010
- Primary completion
- Feb 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and pertuzumab in neuroendocrine carcinoma (NEC), sponsored by SCRI Development Innovations. Primary endpoint: Objective Response Rate at 18 months. Started May 2010; status: completed.
02
Drugs
bevacizumabpertuzumab
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT01121939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01121939.